At MD Anderson, Memorial Sloan Kettering, and Dana-Farber, pancreatic cancer patients are already being screened for KRAS mutations to determine whether they qualify for the newest targeted therapy. At most community oncology practices across the United States, they are not.
That gap — between the academic centers where a new class of pancreatic cancer drugs was tested and the community hospitals where most Americans with the disease are actually treated — is the central challenge facing daraxonrasib, a drug from Revolution Medicines that posted trial results last week showing it cut the risk of death by 60 percent compared to chemotherapy. The results were unprecedented for a RAS inhibitor in pancreatic cancer. The access question is whether the patients who need the drug most will ever know they qualify.
More than 90 percent of pancreatic cancer patients have tumors driven by mutations in RAS proteins. KRAS, the most famous member of that family, was called undruggable for four decades — too smooth, too embedded in the cell's machinery to grab with any drug. Daraxonrasib works by binding to a chaperone protein called cyclophilin A, which then grabs KRAS while it is in its active "on" state, physically blocking the protein from triggering the cascade of signals that tell cancer cells to grow and divide. Taken as a 300-milligram pill once daily, it hits not just the G12C and G12D mutations most commonly targeted in KRAS drug development, but a broad range of variants — and, notably, appears to work even in some patients whose tumors carry no identifiable KRAS mutation at all.
That last detail is the one scientists keep returning to.
The trial enrolled patients with a wide range of RAS variants, plus a cohort whose tumors had no identified RAS mutation. Both groups appeared to benefit, according to Revolution Medicines' press release. The wild-type enrollment — patients who shouldn't respond by the textbook mechanism — has not yet been separately disclosed in the full dataset. "The enrollment of wild-type patients is the scientific outlier that nobody is talking about yet," said Dr. Andrew Aguirre, a gastrointestinal oncologist at Dana-Farber Cancer Institute who was not involved in the study. "It suggests either that our understanding of who responds to RAS inhibition is incomplete, or that the drug is doing something we haven't fully characterized."
"It's the first time we've seen a RAS inhibitor extend median overall survival beyond one year in a Phase 3 pancreatic cancer trial," said Dr. Shubham Pant, a medical oncologist at MD Anderson Cancer Center. "That matters."
In the Phase 3 trial of 441 patients, those taking daraxonrasib survived a median of 13.2 months versus 6.7 months on chemotherapy. The independent data monitoring committee stopped the study early because the benefit was clear enough to be unethical to continue withholding from the control arm.
The access problem is structural. Comprehensive molecular profiling — the test that tells doctors whether a patient's tumor carries the RAS mutations daraxonrasib targets — is standard at major academic cancer centers. It is not standard at the community oncology practices where most Americans with cancer receive care. Without that test, a RAS inhibitor is invisible to the doctor who might prescribe it.
"The drug could be sitting right there, approved and available, and the patients who need it most might never know they qualify," said Dr. Brian Wolpin, a pancreatic cancer researcher at Dana-Farber who was not involved in the study. "Molecular testing rates in community oncology settings are still stubbornly low."
Pancreatic cancer kills roughly 50,000 Americans a year. Five-year survival stands at approximately 12 to 13 percent, according to the most recent data from the American Cancer Society and the SEER registry. For decades, it was a disease that oncologists learned to treat rather than cure.
One patient who has spoken publicly about his experience on daraxonrasib is former U.S. Senator Ben Sasse. After his own pancreatic cancer diagnosis, Sasse enrolled in the trial at an academic medical center. His CA 19-9 tumor marker — a protein whose elevation signals cancer activity — was above 8,000 when he started. It dropped to near-zero. His tumors shrank 76 percent.
"I was basically on my way out," Sasse told STAT News. "I got something I didn't expect. Time."
Daraxonrasib has won Breakthrough Therapy Designation and Orphan Drug Designation from the FDA — dual badges of regulatory urgency that, according to CNBC, together with a Priority Review Voucher the company plans to redeem, could compress the approval timeline to months rather than the standard year-plus review. BioPharma Dive reported that Revolution Medicines' stock rose nearly 40 percent the day results were announced, adding roughly $7 billion to the company's market capitalization, which now exceeds $26 billion. The company has four global Phase 3 trials running — three in pancreatic cancer, one in non-small cell lung cancer — and has been the subject of acquisition rumors, with Merck reportedly exploring a deal that both parties have since denied. Revolution shares have risen nearly 274 percent over the past year.
Side effects were described as manageable. Per CNBC, roughly one in ten patients developed a significant skin rash — a known class effect for KRAS inhibitors — that in most cases resolved with dose interruption or antibiotics. No new safety signals were reported.
The full dataset will be presented at the American Society of Clinical Oncology annual meeting in late May. Some of the most scientifically relevant numbers — progression-free survival by RAS mutation subtype, response rates in the wild-type cohort, long-term follow-up — remain under wraps.
Revolution Medicines spent fifteen years building toward this moment. The company's platform — centered on the idea of targeting RAS in its active state, using a chaperone protein as a structural ally rather than trying to grab KRAS directly — was considered unfashionable for much of that time, as the field focused on other approaches. Now the company is either a pioneering story of scientific persistence or an acquisition target that just became dramatically more expensive, depending on whom you ask.
Daraxonrasib changes what is possible in pancreatic cancer. Whether it changes who gets treated is the question that comes next.
